Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib.

NPJ precision oncology·2026
Same author

De novo biosynthesis of alpinetin enhanced by directed evolution of 5-O-methyltransferase.

Microbial cell factories·2026
Same author

Repurposing of Inhibitors of Plasmodial Aspartate Transcarbamoylase Toward Trypanosoma Cruzi.

ChemMedChem·2026
Same author

A protein-based self-assembled nanoparticle provides an improved malarial vaccine.

Trends in parasitology·2026
Same author

Molecular Characterization of Calu-3 Cells from Submerged to Air-Liquid Interface to Model Lung Infections.

Journal of proteome research·2026
Same author

Enzymatic synthesis of bioactive quinolones and (thio)coumarins by fungal type III polyketide synthases.

The FEBS journal·2025

Related Experiment Video

Updated: Dec 30, 2025

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
07:14

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

472

New directions in antimalarial target validation.

Fernando A Batista1,2, Benjamin Gyau1, Juliana F Vilacha1

  • 1Structural Biology Unit, XB20 Drug Design, Department of Pharmacy, University of Groningen, Groningen, The Netherlands.

Expert Opinion on Drug Discovery
|January 22, 2020
PubMed
Summary

Developing new malaria drugs is crucial due to drug resistance. The protein interference assay (PIA) offers a novel method for rapid in vivo validation of Plasmodial drug targets, aiding antimalarial drug discovery.

Keywords:
Protein oligomerisationdrug target validationmalariaphenotypic mapping

More Related Videos

Assays for the Identification of Novel Antivirals against Bluetongue Virus
12:02

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

14.5K
Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors
05:28

Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors

Published on: May 12, 2022

3.5K

Related Experiment Videos

Last Updated: Dec 30, 2025

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
07:14

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

472
Assays for the Identification of Novel Antivirals against Bluetongue Virus
12:02

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

14.5K
Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors
05:28

Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors

Published on: May 12, 2022

3.5K

Area of Science:

  • Infectious Diseases
  • Parasitology
  • Drug Discovery

Background:

  • Malaria remains a major global health threat, affecting over 40% of the world's population.
  • The emergence of drug-resistant malaria strains necessitates the development of new antimalarial drugs.
  • Current drug target validation methods for malaria parasites (Plasmodium) have limitations.

Purpose of the Study:

  • To review current techniques for validating malaria drug targets.
  • To introduce the protein interference assay (PIA) as a novel tool for rapid in vivo target validation.
  • To demonstrate the potential of PIA in antimalarial drug development.

Main Methods:

  • Review of existing drug target validation techniques in malaria research.
  • Introduction and application of the protein interference assay (PIA).
  • Validation of aspartate metabolism as a druggable pathway using PIA.

Main Results:

  • The protein interference assay (PIA) is presented as an effective tool for rapid in vivo validation of Plasmodial targets.
  • PIA demonstrated the druggability of aspartate metabolism, validating the exploitation of oligomeric interfaces.
  • The study provides proof of concept for PIA's utility in antimalarial drug discovery.

Conclusions:

  • A combination of validation approaches is recommended for future antimalarial drug discovery efforts.
  • The protein interference assay (PIA) is a valuable addition to antimalarial validation tools.
  • PIA shows potential for application to other Plasmodial targets and infectious diseases.